Abstract: TNG908 (Ralometostat) is a novel, brain-penetrant, MTA-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) specifically designed to target cancers harboring methylthioadenosine phosphorylase (MTAP) deletions. MTAP deletion is a frequent genetic event in human cancers, often co-occurring with the loss of the tumor suppressor CDKN2A, and creates a synthetic lethal vulnerability to PRMT5 inhibition. Unlike first-generation PRMT5 inhibitors that lack tumor selectivity and cause dose-limiting hematological toxicities, TNG908 leverages the disease-specific accumulation of methylthioadenosine (MTA) to selectively inhibit PRMT5 in MTAP-deleted cells. Discovered through high-throughput screening and structure-based drug design, TNG908 demonstrates a 15-fold selectivity for MTAP-null cells over wild-type cells. It exhibits strong, dose-dependent antitumor activity across multiple preclinical xenograft models, including glioblastoma, non-small cell lung cancer (NSCLC), and colorectal cancer. Furthermore, its optimized physicochemical properties enable significant blood-brain barrier penetration, making it a promising candidate for central nervous system (CNS) malignancies. TNG908 has entered Phase I/II clinical trials (NCT05275478) for patients with advanced or metastatic MTAP-deleted solid tumors, paving the way for precision oncology approaches utilizing synthetic lethality.
1. Introduction
The advent of comprehensive cancer genome sequencing has highlighted the therapeutic potential of targeting collateral vulnerabilities created by passenger gene deletions. One of the most prevalent and robust synthetic lethal interactions identified is the dependence of MTAP-deleted cancer cells on the activity of protein arginine methyltransferase 5 (PRMT5) [1][2]. The MTAP gene is located on chromosome 9p21 in close proximity to the critical tumor suppressor gene CDKN2A. Consequently, homozygous co-deletion of MTAP occurs in 10-15% of all human cancers, including high frequencies in glioblastoma (GBM), mesothelioma, pancreatic adenocarcinoma, non-small cell lung cancer (NSCLC), and cholangiocarcinoma [1][2].
PRMT5 is an essential type II arginine methyltransferase that regulates transcription, RNA splicing, and the DNA-damage response by symmetrically dimethylating arginine residues on target proteins [1][2]. Early clinical efforts to target PRMT5 utilized S-adenosylmethionine (SAM)-competitive or SAM-uncompetitive inhibitors. However, these first-generation inhibitors lacked selectivity for MTAP-deleted cells, leading to dose-limiting hematological toxicities and a narrow therapeutic index [1][2]. To overcome this, TNG908 was developed as a next-generation, MTA-cooperative PRMT5 inhibitor. By exploiting the unique metabolic environment of MTAP-deleted tumors, TNG908 achieves selective cancer cell killing while sparing normal tissues, and possesses the necessary physicochemical properties to cross the blood-brain barrier (BBB) for the treatment of CNS tumors [1][2].
2. Pharmacological Activity
TNG908 exhibits potent and highly selective pharmacological activity against MTAP-deleted cancers both in vitro and in vivo. In cellular assays, TNG908 inhibits symmetric dimethylarginine (SDMA) marks—the proximal pharmacodynamic biomarker of PRMT5 activity—with an IC50 of 9 nM in MTAP-null cells compared to 180 nM in isogenic MTAP-wild-type (WT) cells [1]. This translates to a 15-fold selectivity in cellular viability assays, where TNG908 selectively kills MTAP-null cancer cells independent of tumor histology [1][2].
In vivo, oral administration of TNG908 drives strong, dose-dependent pharmacodynamic target engagement and antitumor efficacy. In xenograft models representing GBM, NSCLC, and colorectal cancer, TNG908 achieved significant tumor growth inhibition and, in many cases, durable tumor regressions [1][2]. Notably, TNG908 demonstrated a clear therapeutic window in isogenic HCT116 xenograft models, driving 85% tumor growth inhibition in MTAP-null tumors while largely sparing MTAP-WT tumors [2].
A key differentiator of TNG908 is its ability to penetrate the BBB. Pharmacokinetic profiling in non-human primates revealed a cerebrospinal fluid (CSF) to unbound plasma concentration ratio (Kpuu,CSF) of 0.9, indicating excellent brain penetrance [1][2]. This property translated into significant in vivo efficacy in a highly aggressive orthotopic U87MG GBM model, where TNG908 extended median survival by 53 days [1].
3. Molecular Mechanism of Action
The mechanism of action of TNG908 is rooted in the metabolic consequences of MTAP deletion. MTAP is a critical enzyme in the methionine salvage pathway, responsible for metabolizing methylthioadenosine (MTA), a byproduct of polyamine synthesis. In MTAP-deleted cells, MTA accumulates to high intracellular levels. MTA acts as an endogenous, SAM-competitive inhibitor of PRMT5, forming a partial PRMT5·MTA inhibitory complex [1][2].
TNG908 is designed to bind cooperatively with MTA to the PRMT5 enzyme. It functions as a substrate-competitive inhibitor that selectively targets the inactive PRMT5·MTA complex rather than the apo-PRMT5 or PRMT5·SAM complexes [1]. Biochemical double-titration assays demonstrate that TNG908 binds to the PRMT5·MTA complex with a KD of 0.3 nM, representing a 6-fold increase in binding affinity compared to apo-PRMT5 (KD = 1.9 nM) [2]. By trapping the PRMT5 enzyme in this ternary PRMT5·MTA·TNG908 complex, the drug selectively halts PRMT5 activity in MTAP-deleted cells where MTA is abundant, thereby inducing synthetic lethality while sparing MTAP-WT normal cells that rapidly clear MTA [1].
4. Structure-Activity Relationship (SAR)
The discovery of TNG908 originated from a high-throughput screening (HTS) campaign utilizing a peptide displacement assay, which identified a low-molecular-weight oxamide hit compound [2]. Structure-based drug design (SBDD) was subsequently employed to optimize potency, selectivity, and BBB permeability.
Initial SAR exploration focused on the piperidine ring. A "methyl scan" revealed that a trans-5-methyl substitution on the piperidine ring provided a 20-fold increase in biochemical potency by optimally filling a hydrophobic pocket [2]. Further optimization targeted the pyridine ring, which sits in proximity to the MTA/SAM binding pocket. The introduction of a 6-amino group or a carboxamide group allowed for critical hydrogen-bonding interactions with the backbone carbonyl of Glu435 and the side chain of Lys333. These interactions sterically lock Glu435 into a specific rotamer that is compatible with MTA binding but precludes SAM binding, thereby driving the MTA-cooperative selectivity [2].
To achieve CNS penetrance, the research team needed to balance potency with physicochemical properties, specifically reducing the polar surface area (PSA) and minimizing efflux transporter liability (e.g., P-gp/MDR1). While phenol substitutions improved potency via hydrogen bonding with Ser310, they negatively impacted permeability. The breakthrough for TNG908 was the incorporation of a benzothiazole group as a phenol isostere. The benzothiazole engages the Ser310 carbonyl lone pair via a non-traditional C-S σ* orbital interaction. This modification maintained high potency while significantly lowering the PSA, resulting in high passive permeability (MDCKII A-B = 16.4 cm/s) and low efflux, ideal for BBB crossing [2].
5. Current Limitations
Despite its robust preclinical profile, the therapeutic application of TNG908 faces certain limitations. First, while TNG908 drives tumor regressions in approximately 30% of MTAP-deleted xenograft models, some models exhibit only tumor growth inhibition without complete regression, suggesting intrinsic resistance or the presence of parallel survival pathways [1]. Functional genomics screens have identified that the upregulation of MAT2A (which increases SAM levels and lowers the MTA/SAM ratio) or WDR77 (which encodes the PRMT5 co-factor MEP50) can reduce cellular sensitivity to MTA-cooperative PRMT5 inhibitors [1].
Additionally, from a clinical development standpoint, while TNG908 entered a Phase I/II clinical trial (NCT05275478) for patients with MTAP-deleted solid tumors, recruitment of new patients was halted due to portfolio prioritization by the sponsor [1]. This limits the immediate availability of extensive human efficacy and safety data for this specific compound, although it serves as a critical proof-of-concept for brain-penetrant MTA-cooperative inhibitors.
6. Future Perspectives
The future of TNG908 and the broader class of MTA-cooperative PRMT5 inhibitors lies in rational combination strategies and precision patient selection. Preclinical data strongly support combining TNG908 with MAT2A inhibitors (e.g., AG-270), which synergistically lower the SAM/MTA ratio and enhance PRMT5 inhibition, driving complete responses even at sub-therapeutic doses [1]. Furthermore, because MTAP deletion is almost universally co-deleted with CDKN2A, combining TNG908 with CDK4/6 inhibitors (such as abemaciclib or palbociclib) has shown broad synergistic efficacy across multiple tumor models [1]. Abemaciclib is particularly attractive for combination in GBM due to its own brain-penetrant properties.
Given that MTAP deletion occurs in tumors with a high propensity for brain metastasis (such as NSCLC and melanoma) as well as primary brain tumors (GBM), the BBB-penetrant profile of TNG908 provides a distinct clinical advantage over peripherally restricted agents. Future research will likely focus on identifying additional predictive biomarkers beyond MTAP status to stratify patients who will achieve deep, durable regressions, ultimately maximizing the clinical utility of targeting the MTAP/PRMT5 synthetic lethal axis [1][2].
